IMC-002 is under clinical development by ImmuneOncia Therapeutics and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase I drugs for Triple-Negative Breast Cancer (TNBC) have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how IMC-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IMC-002 overview
IMC-002 is under development for the treatment of solid tumors including colorectal cancer, relapsed or refractory lymphomas, solid tumors which include metastatic hepatocellular carcinoma (HCC), metastatic biliary tract cancer, gallbladder cancer, triple-negative breast cancer (TNBC), human epidermal growth factor receptor 2 negative breast cancer (HER2- Breast Cancer), mantle cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, marginal zone B-cell lymphoma and relapsed and refractory hematological tumors. The drug candidate is a fully human IgG monoclonal antibody. It acts by targeting cluster of differentiation 47 (CD47) and cluster of differentiation 20 (CD20). It is administered through intravenous route.
ImmuneOncia Therapeutics overview
ImmuneOncia Therapeutics is an immuno-oncology-centric biopharmaceutical company that engaged in drug development and antibody engineering. It is headquartered in Seongnam, South Korea.
For a complete picture of IMC-002’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
